Weight Loss Studies with Pharmacotherapy
| Author (year) | Nation | Initial BMI (kg/m2) | Number of patients analyzed | Assessment period | Intervention type | Main predictors |
|---|---|---|---|---|---|---|
| Fujioka et al23) (2019) | USA | 36.1 | 6635 | 52 w | Lorcaserin 10 mg, placebo (each with diet, exercise) | Age (+) |
| Wharton et al24) (2019) | Canada | 40.7 | 311 | 6 m | Liraglutide 3 mg with diet and exercise | Age (+), baseline weight (-) |
| Maccora et al25) (2020) | Italy | 38.6 | 100 | 6 m | Liraglutide 0.6 mg (0.6 mg increment when the response was not satisfactory) | Early weight loss (+) |
| Tronieri et al26) (2020) | USA | 38.8 | 150 | 52 w | IBT alone, IBT with liraglutide 3 mg, or IBT-liraglutide combined with a 12 w meal replacement diet (multi-component) | Attendance, dietary self-monitoring, medication adherence (+) |
| Tchang et al27) (2022) | USA | 35.3 | 421 | 2 y | AOM | Initial BMI, AOM usage (+) |
BMI: body mass index, w: week, +: positive correlation, m: month, -: negative correlation, IBT: intensive behavioral therapy, y: year, AOM: anti-obesity medication.
